Big pharma, Partnering

Pfizer in collaboration agreement for lupus study

Posted on 05 May 2015

Tags: ,

23andMe announced the launch of the Lupus Research Study in collaboration with Pfizer.

The companies aim to enroll 5,000 individuals with systemic lupus erythematosus, more commonly known as lupus, into the study to help better understand the genetics of lupus.

The effort is also in collaboration with the Lupus Research Institute, and in concert with Lupus Awareness Month in May.

n addition to genetic information and survey questions, 23andMe will incorporate data from participants' medical records into this research study after obtaining their consent.

This data will be used in the analysis of longitudinal surveys with participants over the course of one year.

 

Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
  • CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time

For further deal information visit Current Agreements (subscription required)

Related

Scorecard: Top partnering deals by value in 2015

View: Top pharmaceutical companies

View: Top biotech companies

Reports: Browse our extensive deal making report portfolio

Print Friendly, PDF & Email

Leave a Reply